Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAP-HETERO study of zolbetuximab + trastuzumab + CapeOX with pembrolizumab by PD-L1 status in HER2-positive and CLDN18.2-positive advanced gastric/GEJ cancer
jRCT2031260183Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of zolbetuximab, trastuzumab, pembrolizumab, oxaliplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Astellas Pharma. Primary endpoint: Progression-free survival. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031260183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260183.